- Global Pharma News & Resources

Paracrine to Present at Landmark’s Health Innovations Forum 2022

Update on advancing multiple late-stage clinical trials for debilitating chronic diseases

SAN DIEGO--(BUSINESS WIRE)--Paracrine, Inc. announced today that it will present at Landmark’s Health Innovations Forum 2022. The invitation-only conference will take place virtually via Zoom on March 2nd and 3rd and will showcase 24 companies developing the latest innovative technologies transforming healthcare.

Paracrine has been selected to present at this year’s Health Innovations Forum based on its potential to bring innovative biologic therapies to market that address major unmet needs in healthcare.

“We are excited to share our progress in advancing Paracrine’s lead products to market approvals with this prestigious group of healthcare investors,” commented Mr. Christopher J. Calhoun, President & CEO of Paracrine. “Armed with robust clinical data and supported by the world’s leading experts in each of our target indications, we are highly confident that this important biologic therapy will become available to physicians and their patients in need within a few short years.”

Paracrine is an emerging biotechnology company developing first-in-class, device-based, autologous cell therapies. Unlike other therapies that target a single mechanism of action, Paracrine Cell Therapy has been shown to have a pleiotropic effect addressing the common underlying pathology of several debilitating chronic diseases. Such effects include improving local blood flow, reducing inflammation, and promoting healing, scar remodeling and tissue repair.

In the past few months, Paracrine has received IDE approvals from the FDA to initiate two pivotal trials in the U.S.: the ASCEND trial in patients with non-healing diabetic foot ulcers and the STAR II trial in patients with hand dysfunction due to diffuse cutaneous scleroderma. The objective of these approval stage trials is to conclusively demonstrate safety and effectiveness, to gain regulatory approval in the U.S. (PMA), and to support optimal reimbursement for this cost-effective cell therapy. The company is also preparing to file an IDE for the ATHENA III trial in patients with chronic heart failure in 2022.


Landmark’s annual Health Innovations Forum is a two-day virtual event that brings together leading investors and innovative device, diagnostic, digital medicine and therapeutic companies to explore the latest innovations and trends that are transforming healthcare. The forum will feature virtual presentations from a select group of innovative companies seeking funding, an expert keynote address and panel discussion, and an investor roundtable.

Health Innovations Forum is a by-invitation event. Registration is restricted to Landmark's investor members and guests. All registration requests are subject to review. For inquiries and additional information, please contact


Paracrine, Inc. is an emerging biotechnology company developing the world’s first device-based autologous pleiotropic cell therapy platform to treat debilitating chronic conditions. Paracrine’s cell therapy platform bears the promise of cost-effectively addressing common underlying pathology of debilitating chronic diseases due to its unique multi-prong mechanisms of action. The company is advancing multiple late-stage IDE clinical trials in the U.S. based on robust prior data.


Media Contact

Richard Laermer
+1 646-517-4340

Paracrine Contact

Christopher Calhoun
+1 858-923-1200

Landmark Angels Contact

Editor Details

  • Company:
    • Businesswire
Last Updated: 02-Feb-2022